Tonix Estimates TONMYA Net Revenue Of $14.0 Million To $15.0 Million For Third Quarter

The company also put its September 30 cash at about $162.8 million, in unaudited figures it says could change.

Share
Tonix Estimates TONMYA Net Revenue Of $14.0 Million To $15.0 Million For Third Quarter

Tonix Pharmaceuticals estimates net revenue for TONMYA of between $14.0 million and $15.0 million for the three months ended September 30, 2026, according to an 8-K filed Thursday. The company also estimated cash and cash equivalents of about $162.8 million at quarter-end.

What the 8-K says

The filing, made under Item 2.02 (results of operations), discloses what the company calls selected preliminary operating results for the September quarter. It gives a range for TONMYA revenue, not a single number, and an approximate cash figure.

The numbers are unaudited estimates prepared by management from assumptions and information available now. The company says they are "subject to revision" after quarter-end closing procedures and the completion of its consolidated financial statements.

Tonix also states that it has not finished its financial closing for the quarter. Its actual results, it says, "could be materially different" from the preliminary figures.

What it changes

For holders, the filing gives an early read on TONMYA revenue and the cash balance before the full quarterly report. It is not a substitute for that report: the company says the figures are not full statements prepared under U.S. generally accepted accounting principles and reviewed by its auditors.

The filing goes further in its caution. It warns that the company may find items requiring material adjustments, and that prospective investors "should exercise caution in relying on this information."

TNXP shares closed at $6.40 in Wednesday's session, up 4.40%, before the filing became public at 7:00 a.m. ET on Thursday, according to market data. That move predates the disclosure.

What to watch

The full third-quarter financial statements, once the closing process is done and the auditors have reviewed them, will show whether the TONMYA range and the cash estimate hold.

The filing is signed by Chief Financial Officer Bradley Saenger and carries the company's own warning that its figures should not be treated as a representation of actual results.

Sources